GPIIbIIIa Inhibitors in the RESCUe and RESURCOR Networks at the Acute Myocardial Infarction (AGIR2)

Civil Hospices of Lyon

Status and phase

Completed

Phase 4

Conditions

Acute Myocardial Infarction

Treatments

Drug: tirofiban

Study type

Interventional

Funder types

Other

Identifiers

NCT00538317

2006-452

Details and patient eligibility

About

In patients with acute myocardial infarction who are managed in the prehospital setting, and who will treated with primary angioplasty, we evaluate the benefit of an early administration of tirofiban, a powerful GPIIbIIIa inhibitors. Patients are randomised to early administration in the ambulance or administration in the cathlab. The primary endpoint is TIMI 2-3 flow in the first coronary opacification of the culprit artery.

Enrollment

320 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Age > 18 years
Information given to the patient and consent obtained
Thoracic pain or symptoms of infarction
Symptoms < 12 hours
ST deviation identified by electrocardiography (ECG) in at least 2 contiguous leads
Transfer time to angioplasty room evaluated by the coordinating doctor as less than 90 minutes (from ECG diagnosis to arrival in angioplasty room)

Exclusion criteria

Physiological or pathological conditions not compatible with a revascularisation procedure (in the acute phase of myocardial infarction (MI)
Administration of fibrinolytics or another antiGPIIBIIIa in the previous seven days
Contraindications to aspirin or tirofiban or heparin
Diagnosed severe kidney failure (dialysis, creatinin > 350µmol/l
Pregnancy
Time for transfer to the angioplasty room evaluated by coordinating doctor as more than 90 minutes
Subject participating in another trial
Subject with high hemorrhagic risk.